This five-year grant will fund a randomized double-blind placebo controlled trial for cannabidiol adjunctive therapy for acute bipolar depression. Cannabidiol (CBD) is a compound derived from cannibis sativa, which has been shown by preliminary studies to have significant therapeutic potential in a number of conditions such as epilepsy, anxiety and schizophrenia, as well as antidepressant effects with few adverse effects in bipolar depressed patients. As the principal investigator, Dr. Yatham will be joined by 16 co-investigators – many of whom are members of the Canadian Network for Mood and Anxiety Treatments (CANMAT) network – to further test the efficacy of cannabidiol as a treatment for the depressive phases of bipolar disorder.
Congratulations to Dr. Yatham on receiving this landmark CIHR project grant!
Read more detailed information about this project on the CIHR Funding Decisions page.